(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | -354.1MM | -291% |
Gross Profit | -181.1MM | -302% |
Cost Of Revenue | 103.5MM | +8% |
Operating Income | 163.1MM | -617% |
Operating Expenses | -344.2MM | -384% |
Net Income | 162.6MM | -593% |
R&D | - | - |
G&A | 85.8MM | +8% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
One product in particular could juice the company's fundamentals, a pundit believes.
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Small cap stocks like those discussed below tend to receive much less attention than their large cap competitors. Shares, which boast a market capitalization between $250 million and $2 billion, remain relatively small. The largest stocks including Nvidia (NASDAQ:NVDA) and Microsoft (NASDAQ:MSFT) are valued into the trillions. It’s no surprise then that they receive the lion’s share of investor attention and capital. As a result, there are a lot of deals to be had among small-cap stocks. Investo
Next Century Growth Investors, LLC, an investment Management Company, released its “SMID Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. October had negative returns from the equity markets in the fourth quarter of 2023, but November and December saw a robust market rally that produced positive returns for […]
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the c
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) shareholders should be happy to see the share price up 28% in the last...
A Relative Strength Rating upgrade for Tandem Diabetes Care shows improving technical performance. Will it continue?
Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SAN DIEGO, March 06, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $275.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previous